Improved immunogenicity with high-dose seasonal influenza vaccine in hiv-infected persons. a single-center, parallel, randomized trial

Annals of Internal Medicine

Volumn 158, Issue 1, 2013, Pages 19-26

  McKittrick, Noah ^a,b   Frank, Ian ^a   Jacobson, Jeffrey M ^a,b   Jo White, C ^a   Kim, Deborah ^a   Kappes, Rosemarie ^a   DiGiorgio, Carol ^a   Kenney, Thomas ^a   Boyer, Jean ^a   Tebas, Pablo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEMAGGLUTINATION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; INDUCED HEADACHE; INFLUENZA VACCINATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN REDNESS; TREATMENT OUTCOME;

EID: 84871897054     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-1-201301010-00005     Document Type: Article

References (42)

1. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol. 2009;45:174-8. [PMID: 19540156]
2. Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol. 2000;10:119-33. [PMID: 10713598]
3. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493-504. [PMID: 19628174]
4. Cohen JP, Macauley C. Susceptibility to influenza A in HIV-positive patients [Letter]. JAMA. 1989;261:245. [PMID: 2909018]
5. Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, Wong SJ, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32: 1784-91. [PMID: 11360221]
6. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007;56(RR-6):1-54. [PMID: 17625497]
7. Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr. 2003;34:304-7. [PMID: 14600576]
8. Radwan HM, Cheeseman SH, Lai KK, Ellison III RT. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31:604-6. [PMID: 10987729]
9. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest. 1990;98:33-7. [PMID: 2361409]
10. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161:441-6. [PMID: 11176770]
11. Gilsdorf A, Poggensee G; Working Group Pandemic Influenza A(H1N1)v. Influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill. 2009;14. [PMID: 19712649]
12. Oliveira W, Carmo E, Penna G, Kuchenbecker R, Santos H, Araujo W, et al; Surveillance Team for the pandemic influenza A(H1N1) 2009 in the Ministry of Health. Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI) [Editorial]. Euro Surveill. 2009;14. [PMID: 19883548]
13. Archer B, Cohen C, Naidoo D, Thomas J, Makunga C, Blumberg L, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill. 2009;14. [PMID: 19883549]
14. Reyes-Terán G, de la Rosa-Zamboni D, Ormsby CE, Vázquez-Pérez J, Ablanedo-Terrazas Y, Vega-Barrientos R, et al. Clinical features of subjects infected with HIV and H1N1 influenza virus. In: 17th Conference of Retrovirus and Opportunistic Infections; 16-19 February 2010; San Francisco, CA. Abstract 803LB.
15. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010:CD001269. [PMID: 20614424]
16. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol. 1983;37:529-49. [PMID: 6357060]
17. Ennis FA, Mayner RE, Barry DW, Manischewitz JE, Dunlap RC, Verbonitz MW, et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis. 1977;136 Suppl:S397-406. [PMID: 606763]
18. Brydak LB, Hryniewicz HJ, Machala M, Horban A. Humoral response to influenza vaccination in HIV-infected patients. Clin Drug Investig. 1999;17: 441-9.
19. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15:253-9. [PMID: 18003811]
20. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12:F217-23. [PMID: 9863863]
21. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262:779-83. [PMID: 2787416]
22. Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med. 1988;109:383-8. [PMID: 2970238]
23. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med. 1987;109:545-9. [PMID: 3572201]
24. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20 Suppl 5:B29-32. [PMID: 12477415]
25. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al; Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIVinfected individuals. AIDS. 2010;24:2187-92. [PMID: 20616698]
26. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Mühlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48:1402-12. [PMID: 19361304]
27. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis. 1999;28:541-7. [PMID: 10194075]
28. Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, Kimura S, et al; HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39:167-73. [PMID: 15905732]
29. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-29. [PMID: 15356773]
30. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1-52. [PMID: 19644442]
31. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J. 1973;49:152-8. [PMID: 4802501]
32. Palache AM, Beyer WE, Sprenger MJ, Masurel N, de Jonge S, Vardy A, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine. 1993;11:3-9. [PMID: 8427034]
33. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of highdose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172-80. [PMID: 19508159]
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: U.S. Department of Health and Human Services; 2011:1-166. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 17 March 2012.
35. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIVinfected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138-46. [PMID: 21148532]
36. Monto AS. Seasonal influenza and vaccination coverage. Vaccine. 2010;28 Suppl 4:D33-44. [PMID: 20713259]
37. Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29:1359-63. [PMID: 21185423]
38. Overton ET. Sometimes, more is better [Editorial]. J Infect Dis. 2012;205: 697-9. [PMID: 22275400]
39. Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, et al; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6:e17758. [PMID: 21512577]
40. El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012; 205:703-12. [PMID: 22275399]
41. Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52: 122-7. [PMID: 21148530]
42. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6: e16496. [PMID: 21304982]